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The spread of carbapenemase-producing 
Enterobacteriaceae (CPE) is a threat to healthcare 
delivery, although its extent differs substantially from 
country to country. In February 2013, national experts 
from 39 European countries were invited to self-assess 
the current epidemiological situation of CPE in their 
country. Information about national management 
of CPE was also reported. The results highlight the 
urgent need for a coordinated European effort on early 
diagnosis, active surveillance, and guidance on infec-
tion control measures.
The present report summarises the results from 39 
European countries of a self-assessment of the epide-
miological stage and the management of carbapene-
mase-producing Enterobacteriaceae (CPE) at national 
level.
Background
CPE are an emerging threat to healthcare and are fre-
quently resistant to many other antibiotics than car-
bapenems [1,2] leaving few treatment options. The 
extent, to which healthcare systems have already been 
affected, however, differs substantially from country 
to country. Following a previous initiative, a group of 
European experts is implementing the European Survey 
on CPE (EuSCAPE) in an effort to update assessments 
of the nature and scale of CPE spread in Europe [3]. The 
current programme receives financial support from the 
European Centre for Disease Prevention and Control 
(ECDC). The aim of this study is to obtain a more accu-
rate and timely estimate of CPE prevalence in European 
countries and to support reference laboratory-capacity 
building to prevent and control the spread of CPE in 
Europe. 
Development of a questionnaire and collection of 
information 
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A Scientific Advisory Board of European experts in the 
field of carbapenemase-producing bacteria was invited 
to provide scientific advice in support of the EuSCAPE 
programme management team. A questionnaire was 
devised and modified from a ‘field-tested’ version 
used during previous similar surveys [3]. The question-
naire was divided into two sections. The first section 
(13 questions) explored the experts’ knowledge and 
awareness of the current occurrence of CPE according 
to a previously-established epidemiological staging 
system [1,3]. In brief, the system captures seven con-
secutive stages in the national spread of these organ-
isms. The seven stages are described in Table 1.
The second section (22 questions) collected infor-
mation about existing requirements, structures and 
guidance documents for reporting, surveillance, use 
of reference laboratory services and infection control 
for CPE. The questionnaire is available from the corre-
sponding author. 
In each of the 39 European countries (i.e. 27 European 
Union (EU) Member States, all European Economic 
Area (EEA)/ European Free Trade Association (ETFA) 
countries except Lichtenstein, and all EU enlargement 
countries, as well as Israel), a national expert (NE) 
with acknowledged laboratory and/or epidemiologi-
cal experience was identified (for the United Kingdom 
two NEs participate in this questionnaire survey). 
The NEs were chosen among European Antimicrobial 
Resistance Surveillance Network (EARS-Net) contact 
points, experts from national reference diagnostic 
laboratories and ECDC-coordinating competent bodies. 
The list of NEs was validated by ECDC and represents 
the EuSCAPE Working Group. The NEs were invited to 
answer the questionnaire online (http://SurveyMonkey.
net, SurveyMonkey Corporation, Portland, USA). 
Answers from the NEs were compiled and analysed. 
When necessary, NEs were contacted by e-mail or 
telephone for clarification, and corrections were made 
accordingly. The epidemiological stage of some coun-
tries was considered as uncertain when (i) the NE 
reported a lack of awareness about the current epide-
miology of CPE in their country, (ii) the answer of the 
NE indicated considerable underdetection and underre-
porting of CPE in their country, (iii) the comments made 
by the NE by e-mail or telephone indicated uncertainty 
and/or (iv) when frequent introductions into other coun-
tries have been described but the NE could not inde-
pendently support this observation by own sources. 
In the maps (Figure), this uncertainty was indicated by 
displaying the respective country as hatched.
Results
All NEs  completed the online questionnaire. Thirty-
seven NEs declared that they were aware of the current 
epidemiology of CPE in their country and all rated the 
occurrence and spread of CPE in their country using the 
previously established epidemiological staging system 
(Figure and Table 1). Nevertheless, only 26 NEs could 
self-assess their current situation with certainty. 
Three countries (Iceland, Montenegro and the former 
Yugoslav Republic of Macedonia) reported no cases of 
CPE in their country. Sporadic cases, single or sporadic 
hospital outbreaks were reported by NEs from 22 coun-
tries. For 11 countries, regional or national spread was 
reported, whereas for three countries (Greece, Italy 
and Malta) NEs reported that CPE are regularly isolated 
from patients in most hospitals, corresponding to the 
endemic stage (Table 1). 
Among the 31 countries that participated in both the 
2010 and 2013 assessments, 17 reported a higher stage 
by 2013; likewise, by 2013, the number of countries 
with regional or inter-regional spread or an endemic 
situation increased from seven to 13 (Table 1). Some 
countries expressed concerns that underdetection or 
Table 1
Description of the epidemiological stages of carbapenemase-producing Enterobacteriaceae (CPE)
Epidemiological scale Description Stage
No cases reported No cases reported 0
Sporadic occurence Single cases, epidemiologically unrelated 1
Single hospital outbreak Outbreak defined as two or more epidemiologically related cases in a single institution 2a
Sporadic hospital outbreaks Unrelated hospital outbreaks with independent, i.e. epidemiologically unrelated introduction or different strains, no autochthonous inter-institutional transmission reported 2b
Regional spread More than one epidemiologically related outbreak confined to hospitals that are part of a regional referral network, suggestive of regional autochthonous inter-institutional transmission 3
Inter-regional spread Multiple epidemiologically related outbreaks occurring in different health districts, suggesting inter-regional autochthonous inter-institutional transmission 4
Endemic situation Most hospitals in a country are repeatedly seeing cases admitted from autochthonous sources 5
The table was reproduced from reference [3].
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Figure 
Occurrence of carbapenemase-producing Enterobacteriaceae (CPE) in 39 European countries based on self-assessment by 
respective national experts, 2013
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A Overall European situation regarding CPE using an epidemiological scale of nationwide expansion
B Geographic distribution of CPE by resistance mechanism using the same epidemiological scale
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KPC: Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae; NDM New Delhi metallo-beta-lactamase; OXA-48: carbapenem-
hydrolysing oxacillinase-48; VIM: Verona integron-encoded metallo-beta-lactamase.
More details on the epidemiological stages are given in the manuscript Table 1.
In some countries, the epidemiological stage might not represent the true extent of the spread of CPE as it is a subjective judgment by 
national experts. Uncertainty about the epidemiological stage of a country is indicated by hatching. Results presented here reflect the 
uncertainty at the time of the survey. For Portugal, case notification and submission of isolates became mandatory on 21 February 2013.
4 www.eurosurveillance.org
Table 2
Comparison of epidemiological stages of carbapenemase-producing Enterobacteriaceae (CPE) in 39 European countries, 2010, 
2012 and 2013
Country
Epidemiological stage for 
spread of CPE Direction 
of change 
(2010 
compared to 
2013)d
Grundmann 
et al., 
2010a
Canton et 
al., 2012b 2013
c
Albania NA NA 2a NA
Austria 0 1 2b
Belgium 2b 3 3
Bosnia and 
Herzegovina 1 1 1
Bulgaria 0 NA 2a
Croatia 1 1 3
Cyprus 2a NA 2a
Czech Republic 1 1 2b
Denmark 1 1 1
Estonia 0 NA 2a
Finland 1 1 2a
France 3 4 3 −e
Germany 3 3 3
Greece 5 5 5
Hungary 3 2a 4
Iceland 0 0 0
Ireland 1 1 4
Israel 5 5 4
Italy 4 5 5
Kosovof NA 1 3 NA
Latvia 1 NA 1
Lithuania 1 NA 1
Luxembourg NA 1 1 NA
Malta 1 NA 5
Montenegro NA 1 0 −g
Netherlands 2a 2b 2b
Norway 2a 2a 2a
Poland 4 4 3 −e
Portugal 1 1 1
Romania 1 1 1
Serbia NA 1 1 NA
Slovakia NA NA 2b NA
Slovenia 0 1 1
Spain 2b 2b 3
Sweden 2a 2a 2b
Switzerland 1 1 2b
The Former 
Yugoslav 
Republic of 
Macedonia
NA NA 0 NA
Turkey NA 4 2a −g
United 
Kingdom 2b 3 3
NA: not available.
The epidemiological staging system, developed in 2010, is based 
on seven levels [3].  Stage 0: no case reported; stage 1: sporadic 
occurrence whereby only single cases are reported; stage 
2a: single hospital outbreak reported whereby an outbreak is 
defined as two or more epidemiologically-associated cases 
with indistinguishable geno- or phenotype; stage 2b: sporadic 
hospital outbreaks reported whereby more than one hospital 
outbreak is reported but all outbreaks are epidemiologically 
unrelated or caused by different clones (no autochthonous inter-
institutional transmission); stage 3: regional spread whereby 
more than one epidemiologically-related hospital outbreak is 
reported, but confined to the same region or health district 
(regional autochthonous inter-institutional transmission); stage 
4: inter-regional spread whereby multiple epidemiologically-
related hospital outbreaks are reported from different regions or 
health districts (inter-regional autochthonous inter-institutional 
transmission); and stage 5: endemic situation whereby most 
hospitals in a country are constantly seeing cases admitted from 
autochthonous sources. 
The epidemiological stage of a country may not reflect the true 
extent of the spread of CPE, as it is based on the subjective 
judgment of the responding national expert in 2010 and 2013 
and the opinion of the authors of a review in 2012. 
Some of the countries were not included in the 2010 survey and/or 
the 2012 review and their epidemiological stage is consequently 
indicated as ‘not available’ (NA).
a  The results were based on data obtained through a European-
wide consultation during a workshop at the Netherlands’s 
National Institute for Public Health and the Environment (RIVM) 
on 29 and 30 April 2010 [3].
b  The results were based on the subjective analyses of the 
literature available at the time of the publication [1]. 
c  This online survey (February 2013). 
d   = increase in the epidemiological stage,  = decrease in the 
epidemiological stage and  = unchanged epidemiological 
stage. A dash indicates that there are discrepancies between 
the results of the 2012 review and the 2013 survey, whereby no 
direction of change can be given.
e  For France and Poland, discrepancies between results from 
the 2012 review and the 2013 survey are probably due to the 
subjective assessment by different experts. 
f  This designation is without prejudice to positions on status, 
and is in line with United Nations Security Council resolution 
1244/99 and the International Court of Justice Opinion on the 
Kosovo declaration of independence.
g  For Montenegro and Turkey, discrepancies between results from 
the 2012 review and the 2013 survey underline the uncertainty of 
stage designation for these countries. 
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underreporting, or both, could affect the certainty of 
the stage of their countries (Figure). 
Thirty-three of the NEs indicated that Klebsiella pneu-
moniae was the most frequent Enterobacteriaceae 
species to produce carbapenemases in their country. 
Overall, K. pneumoniae carbapenemase-producing 
Enterobacteriaceae (KPC) have attained the widest 
distribution, whereas strains with New Delhi metallo 
(NDM)-beta-lactamase – although responsible for 
occasional hospital outbreaks in few countries – have 
not reached such a wide distribution in European coun-
tries (Figure). 
Table 2 displays the level of national management of 
CPE, based on existing surveillance, reference systems, 
and guidance in the 39 countries. Thirty and 28 of 39 
countries reported having a dedicated surveillance sys-
tem for CPE and a dedicated reference laboratory for 
CPE, respectively. Twenty-three reported having a sys-
tem to notify CPE cases to health authorities, mostly 
on a mandatory basis. Only 21 countries reported hav-
ing national recommendations or guidelines on infec-
tion control measures to prevent the spread of CPE; 
one country reported having such recommendation or 
guideline in preparation.
Countries that were uncertain about their epidemio-
logical stages had on average 1.9 national manage-
ment documents regulating surveillance and response 
structures. In contrast, those who were more certain 
about their epidemiological stages had on average 4.7 
(p-value < 0.001; Wilcoxon Rank Sum Test).
Discussion
The results of this online survey, performed in February 
2013, show that, based on the knowledge and judg-
ment of NEs, CPE are continuing to spread in Europe. 
Although most countries reported only single hospital 
outbreaks, the epidemiological situation has deterio-
rated over the past three years. Among the 31 countries 
that participated in both 2010 and 2013 assessments, 
17 countries were upgraded to a higher epidemiologi-
cal stage (Table 1). Three countries that reported spo-
radic occurrence or single hospital outbreaks of CPE 
in 2010 are now witnessing regional or inter-regional 
spread, or even an endemic situation. Malta moved 
from having sporadic cases to an endemic situation, 
although by nature of its small size, the intermedi-
ate epidemiological stages have little relevance. 
The influx of injured refugees from Libya in 2011, is 
believed to have contributed to an increase in car-
bapenem-hydrolysing oxacillinase (OXA)-48-positive 
Enterobacteriaceae (M. Borg, personal communication, 
April 2013). In Italy, a sporadic occurrence of Verona 
integron-encoded metallo-beta-lactamase (VIM)-
producing Enterobacteriaceae from 2008, accentuated 
by a single hospital outbreak, has been overtaken by 
the wide dissemination of KPC-positive K. pneumoniae 
strains to many healthcare institutions. [4-9]. The situ-
ation in Hungary has evolved in the opposite direction: 
in 2010, concern centred upon a single clone of KPC-
2-positive K. pneumoniae that had attained regional 
distribution, whereas VIM-4-positive strains were only 
reported sporadically, but have now spread nation-
wide [3,10]. Overall, KPC-positive Enterobacteriaceae 
still have the widest distribution among CPE in Europe, 
but rising numbers of OXA-48-positive isolates are 
reported, making OXA-48 the most frequently detected 
carbapenemase in Belgium, France and Malta. Despite 
the attention that NDM has received when associated 
with introductions from the Indian subcontinent, the 
current numbers of reports by European countries are 
still relatively modest compared to the other carbapen-
emases [11]. The United Kingdom, however, continues 
to report more NDM-positive isolates than most other 
European countries [3,12].
The NEs completed the questionnaire to the best of 
their knowledge, but these were subjective assess-
ments that may have underestimated the true extent of 
the spread of CPE. Underdetection and underreporting 
were pointed out by respondents in several countries, 
leading to uncertainty about the true epidemiological 
stage (Figure). In particular, this applied to countries 
from which introductions into other countries have 
been described but where NEs could not independently 
assess the extent of CPE spread. Underdetection and 
underreporting of CPE also coincided with weaker ref-
erence laboratory infrastructures and the absence of 
national recommendations for submission to national 
reference laboratories and for reporting to health 
authorities, thus suggesting that the true extent of CPE 
occurrence in Europe is still underestimated. At the 
same time, countries with strict screening policies and 
good surveillance are more likely to report advanced 
epidemiological stages also affecting the comparabil-
ity of the assessment. 
The keys to success in preventing the establishment of 
CPE are, firstly, early detection through good diagnos-
tic practices, secondly, containment of spread through 
patient and contact screening as well as infection 
control measures. An increasing number of countries 
have reacted and implemented measures as indicated 
by the increasing availability of a recommendation or 
guideline on infection control measures to prevent the 
spread of CPE [12]. Still 18 countries surveyed lacked 
such guidance and the same number of countries 
lacked relevant guidance for submission of isolates 
to national reference laboratories [12]. The results of 
the present report underscore the urgent need for an 
upgrading of laboratory standards to enable active sur-
veillance and preventive action. To this purpose, the 
EuSCAPE programme aims to build a laboratory-based 
network for CPE detection in Europe.
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Table 3
National management of carbapenemase-producing Enterobacteriaceae (CPE) in 39 European countries, 2013
Country
National 
system for 
surveillance
Officially 
nominated 
national 
reference 
laboratory
National 
recommendation 
or guideline 
for submitting 
isolates to 
national expert 
or reference 
laboratories
Agreed criteria 
or a policy for 
submitting 
isolates to 
national expert 
or reference 
laboratoriesa
National 
recommendation 
or obligation 
for reporting 
(notification) to 
health authorities
National 
recommendation 
or guideline on 
infection control 
measures
Albania
Austria b
Belgium b
Bosnia and Herzegovina
Bulgaria c
Croatia c
Cyprus
Czech Republic c
Denmark
Estonia -d
Finland c
France c
Germany
Greece c e
Hungary c
Iceland c
Ireland c
Israel c
Italy c,f
Kosovog
Latviae c
Lithuania
Luxembourg c
Malta e
Montenegro
Norway c
Poland c
Portugal c
Romania -d
Serbia
Slovakia b
Slovenia
Spain b
Sweden c
Swizterland
The Former Yugoslav Republic 
of Macedonia
c
The Netherlands c
Turkey
United Kingdom
In the table cells, a dot in signifies ‘in place’ and the absence of a dot signifies ‘absent’.
a  Agreed criteria or policy (including minimum inhibitory concentration (MIC) cut-off, species and resistance confirmation, epidemiological 
typing) to submit CPE isolates to a national reference laboratory.
b  Voluntary notification to health authorities.
c  Mandatory notification to health authorities.
d  Country reporting carbapenem-resistant invasive isolates (Klebsiella pneumoniae and Escherichia coli to the European Antimcirobial 
resistance Surveillance Network (EARS-Net)).
e  Only in case of outbreaks.
f  Only for bacteraemia cases.
g  This designation is without prejudice to positions on status, and is in line with United Nations Security Council resolution 1244/99 and the 
International Court of Justice Opinion on the Kosovo declaration of independence.
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The European Survey on Carbapenemase-Producing 
Enterobacteriaceae (EuSCAPE) working group (national 
experts)
Albania – Andi Koraqi; Austria – Petra Apfalter; Belgium 
– Youri Glupczynski; Bosnia and Herzegovia – Tatjana 
Marković; Bulgaria – Tanya Strateva; Croatia – Arjana 
Tambić Andrašević; Cyprus – Despo Pieridou-Bagatzouni; 
Czech Republic – Jaroslav Hrabak; Denmark – Anette 
M. Hammerum, Estonia – Marina Ivanova; Finland – Jari 
Jalava; France – Bruno Coignard; Germany – Martin Kaase; 
Greece – Alkis Vatopoulos; Hungary – Ákos Tóth; Iceland – 
Hordur Hardarson; Ireland – Teck Wee Boo; Israel – Yehuda 
Carmeli; Italy – Annalisa Pantosti; Kosovo – Lul Raka; 
Latvia – Arta Balode; Lithuania – Jolanta Miciuleviciene; 
Luxembourg – Monique Perrin-Weniger; Malta – Nina 
Nestorova; Montenegro – Gordana Mijović; The Netherlands 
– Henk Bijlmer; Norway – Ørjan Samuelsen; Poland – Dorota 
Żabicka; Portugal – Manuela Caniça; the former Yugoslav 
Republic of Macedonia – Ana Kaftandzieva; Romania – Maria 
Damian; Scotland – Camilla Wiuff; Serbia – Zora Jelesić; 
Slovakia – Milan Nikš; Slovenia – Mateja Pirš; Spain – Jesùs 
Oteo; Sweden – Christian G. Giske; Switzerland – Andrea 
Endimiani; Turkey – Deniz Gür; United Kingdom – Neil 
Woodford.
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